{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:10:27Z","timestamp":1794330627897,"version":"4.9.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":905,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Lumacaftor\/ivacaftor (LUM\/IVA) was shown to be safe and well tolerated in children 2 through 5 years of age with cystic fibrosis (CF) homozygous for F508del-CFTR in a Phase 3 open-label study. Improvements in sweat chloride concentration, markers of pancreatic function, and lung clearance index2.5 (LCI2.5), along with increases in growth parameters, suggested the potential for early disease modification with LUM\/IVA treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To further assess the effects of LUM\/IVA on CF disease progression in children 2 through 5 years of age using chest magnetic resonance imaging (MRI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This Phase 2 study had two parts: a 48-week, randomized, double-blind, placebo-controlled treatment period in which children 2 through 5 years of age with CF homozygous for F508del-CFTR received either LUM\/IVA or placebo (Part 1) followed by an open-label period in which all children received LUM\/IVA for an additional 48 weeks (Part 2). The results from Part 1 are reported. The primary endpoint was absolute change from baseline in chest MRI global score at Week 48. Secondary endpoints included absolute change in LCI2.5 through Week 48 and absolute changes in weight-for-age, stature-for-age, and body mass index\u2013for-age z-scores at Week 48. Additional endpoints included absolute changes in sweat chloride concentration, fecal elastase-1 levels, serum immunoreactive trypsinogen, and fecal calprotectin through Week 48. The primary endpoint was analyzed using Bayesian methods, where the actual Bayesian posterior probability of LUM\/IVA being superior to placebo in the chest MRI global score at Week 48 was calculated using a vague normal prior distribution; secondary and additional endpoints were analyzed using descriptive summary statistics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifty-one children were enrolled and received LUM\/IVA (n\u2009=\u200935) or placebo (n\u2009=\u200916). For the change in chest MRI global score at Week 48, the Bayesian posterior probability of LUM\/IVA being better than placebo (treatment difference, &amp;lt;0; higher score indicates greater abnormality) was 76%; the mean treatment difference was \u22121.5 (95% credible interval, \u22125.5 to 2.6). Treatment with LUM\/IVA also led to within-group numerical improvements in LCI2.5, growth parameters, and biomarkers of pancreatic function as well as greater decreases in sweat chloride concentration compared with placebo from baseline through Week 48. Safety data were consistent with the established safety profile of LUM\/IVA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This placebo-controlled study suggests the potential for early disease modification with LUM\/IVA treatment, including that assessed by chest MRI, in children as young as 2 years of age.<\/jats:p>\n                    <jats:p>Clinical trial registered with www.clinicaltrials.gov (NCT 03625466).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1513\/annalsats.202208-684oc","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T11:56:31Z","timestamp":1679399791000},"page":"1144-1155","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":25,"title":["Effects of Lumacaftor\/Ivacaftor on Cystic Fibrosis Disease Progression in Children 2 through 5 Years of Age Homozygous for\n                    <i>F508del-CFTR<\/i>\n                    : A Phase 2 Placebo-controlled Clinical Trial"],"prefix":"10.1093","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6941-8315","authenticated-orcid":false,"given":"Mirjam","family":"Stahl","sequence":"first","affiliation":[{"name":"Department of Pediatric Respiratory Medicine, Immunology, and Critical Care Medicine and"},{"name":"German Center for Lung Research, Associated Partner Site, Berlin, Germany"},{"name":"Berlin Institute of Health at Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jobst","family":"Roehmel","sequence":"additional","affiliation":[{"name":"Department of Pediatric Respiratory Medicine, Immunology, and Critical Care Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Eichinger","sequence":"additional","affiliation":[{"name":"Translational Lung Research Center Heidelberg, German Center for Lung Research, Heidelberg, Germany"},{"name":"Department of Diagnostic and Interventional Radiology"},{"name":"Department of Diagnostic and Interventional Radiology with Nuclear Medicine, Thoraxklinik, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Doellinger","sequence":"additional","affiliation":[{"name":"Department of Radiology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz","family":"Naehrlich","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Justus Liebig University Giessen, Giessen, Germany"},{"name":"Universities of Giessen and Marburg Lung Center, German Center for Lung Research, Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias V.","family":"Kopp","sequence":"additional","affiliation":[{"name":"Pediatric Respiratory Medicine, Department of Pediatrics, Inselspital, University of Bern, Bern, Switzerland"},{"name":"Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9582-1025","authenticated-orcid":false,"given":"Anna-Maria","family":"Dittrich","sequence":"additional","affiliation":[{"name":"Department for Pediatric Pulmonology, Allergology, and Neonatology and"},{"name":"BREATH, German Center for Lung Research, Hannover Medical School, Hannover, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Lee","sequence":"additional","affiliation":[{"name":"Vertex Pharmaceuticals Incorporated, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Sommerburg","sequence":"additional","affiliation":[{"name":"Translational Lung Research Center Heidelberg, German Center for Lung Research, Heidelberg, Germany"},{"name":"Division of Pediatric Pulmonology and Allergy and Cystic Fibrosis Center, Department of Pediatrics, Heidelberg University Hospital, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Tian","sequence":"additional","affiliation":[{"name":"Vertex Pharmaceuticals Incorporated, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tu","family":"Xu","sequence":"additional","affiliation":[{"name":"Vertex Pharmaceuticals Incorporated, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Wu","sequence":"additional","affiliation":[{"name":"Vertex Pharmaceuticals Incorporated, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniket","family":"Joshi","sequence":"additional","affiliation":[{"name":"Vertex Pharmaceuticals Incorporated, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Partha","family":"Ray","sequence":"additional","affiliation":[{"name":"Vertex Pharmaceuticals Incorporated, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret E.","family":"Duncan","sequence":"additional","affiliation":[{"name":"Vertex Pharmaceuticals Incorporated, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6962-037X","authenticated-orcid":false,"given":"Mark O.","family":"Wielp\u00fctz","sequence":"additional","affiliation":[{"name":"Translational Lung Research Center Heidelberg, German Center for Lung Research, Heidelberg, Germany"},{"name":"Department of Diagnostic and Interventional Radiology"},{"name":"Department of Diagnostic and Interventional Radiology with Nuclear Medicine, Thoraxklinik, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4057-2199","authenticated-orcid":false,"given":"Marcus A.","family":"Mall","sequence":"additional","affiliation":[{"name":"Department of Pediatric Respiratory Medicine, Immunology, and Critical Care Medicine and"},{"name":"German Center for Lung Research, Associated Partner Site, Berlin, Germany"},{"name":"Berlin Institute of Health at Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,8,1]]},"reference":[{"key":"2026012203282184300_bib1","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1164\/rccm.201910-1943SO","article-title":"Cystic fibrosis: emergence of highly effective targeted therapeutics and potential clinical implications","volume":"201","author":"Mall","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203282184300_bib2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026012203282184300_bib3","author":"Zolin","year":"2020"},{"key":"2026012203282184300_bib4","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1164\/rccm.201503-0578OC","article-title":"Sustained benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data","volume":"192","author":"Sawicki","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203282184300_bib5","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(16)30427-1","article-title":"Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study","volume":"5","author":"Konstan","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2026012203282184300_bib6","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/thoraxjnl-2017-210394","article-title":"Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor","volume":"73","author":"Bessonova","year":"2018","journal-title":"Thorax"},{"key":"2026012203282184300_bib7","volume-title":"Orkambi (lumacaftor\/ivacaftor) [Summary of product characteristics]","year":"2019"},{"key":"2026012203282184300_bib8","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S2213-2600(18)30460-0","article-title":"Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study","volume":"7","author":"McNamara","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2026012203282184300_bib9","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jpeds.2009.05.005","article-title":"Bronchiectasis in infants and preschool children diagnosed with cystic fibrosis after newborn screening","volume":"155","author":"Stick","year":"2009","journal-title":"J Pediatr"},{"key":"2026012203282184300_bib10","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S2213-2600(13)70026-2","article-title":"Early lung disease in cystic fibrosis","volume":"1","author":"Grasemann","year":"2013","journal-title":"Lancet Respir Med"},{"key":"2026012203282184300_bib11","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1301725","article-title":"Risk factors for bronchiectasis in children with cystic fibrosis","volume":"368","author":"Sly","year":"2013","journal-title":"N Engl J Med"},{"key":"2026012203282184300_bib12","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1136\/thoraxjnl-2011-200912","article-title":"Progression of early structural lung disease in young children with cystic fibrosis assessed using CT","volume":"67","author":"Mott","year":"2012","journal-title":"Thorax"},{"key":"2026012203282184300_bib13","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/thoraxjnl-2020-216085","article-title":"Time to get serious about the detection and monitoring of early lung disease in cystic fibrosis","volume":"76","author":"Bayfield","year":"2021","journal-title":"Thorax"},{"key":"2026012203282184300_bib14","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.ejrad.2011.02.045","article-title":"Morphologic and functional scoring of cystic fibrosis lung disease using MRI","volume":"81","author":"Eichinger","year":"2012","journal-title":"Eur J Radiol"},{"key":"2026012203282184300_bib15","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1002\/ppul.23537","article-title":"Early detection and sensitive monitoring of CF lung disease: prospects of improved and safer imaging","volume":"51","author":"Mall","year":"2016","journal-title":"Pediatr Pulmonol"},{"key":"2026012203282184300_bib16","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1002\/ppul.24931","article-title":"Novel imaging techniques for cystic fibrosis lung disease","volume":"56","author":"Goralski","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"2026012203282184300_bib17","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1164\/rccm.201604-0893OC","article-title":"Comparison of lung clearance index and magnetic resonance imaging for assessment of lung disease in children with cystic fibrosis","volume":"195","author":"Stahl","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203282184300_bib18","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1164\/rccm.201309-1659OC","article-title":"Magnetic resonance imaging detects changes in structure and perfusion, and response to therapy in early cystic fibrosis lung disease","volume":"189","author":"Wielp\u00fctz","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203282184300_bib19","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1164\/rccm.202102-0278OC","article-title":"Magnetic resonance imaging detects progression of lung disease and impact of newborn screening in preschool children with cystic fibrosis","volume":"204","author":"Stahl","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203282184300_bib20","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S1569-1993(21)00981-4","article-title":"WS12.1 An exploratory study to determine the impact of lumacaftor\/ivacaftor (LUM\/IVA) on disease progression in children 2 through 5 years of age with cystic fibrosis homozygous for F508del-CFTR (F\/F)","volume":"20","author":"Stahl","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2026012203282184300_bib21","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"key":"2026012203282184300_bib22","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S2213-2600(17)30215-1","article-title":"Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial","volume":"5","author":"Ratjen","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2026012203282184300_bib23","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/jmri.25978","article-title":"Assessment of pulmonary structure-function relationships in young children and adolescents with cystic fibrosis by multivolume proton-MRI and CT","volume":"48","author":"Pennati","year":"2018","journal-title":"J Magn Reson Imaging"},{"key":"2026012203282184300_bib24","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1513\/AnnalsATS.202008-1054OC","article-title":"Effects of lumacaftor-ivacaftor on lung clearance index, magnetic resonance imaging, and airway microbiome in Phe508del homozygous patients with cystic fibrosis","volume":"18","author":"Graeber","year":"2021","journal-title":"Ann Am Thorac Soc"},{"key":"2026012203282184300_bib25","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1164\/rccm.202201-0219OC","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy on lung clearance index and magnetic resonance imaging in patients with cystic fibrosis and one or two F508del alleles","volume":"206","author":"Graeber","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203282184300_bib26","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.3390\/jcm11154277","article-title":"Early effects of elexacaftor-tezacaftor-ivacaftor therapy on magnetic resonance imaging in patients with cystic fibrosis and advanced lung disease","volume":"11","author":"Macconi","year":"2022","journal-title":"J Clin Med"},{"key":"2026012203282184300_bib27","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jcf.2022.03.011","article-title":"Magnetic resonance imaging detects improvements of pulmonary and paranasal sinus abnormalities in response to elexacaftor\/tezacaftor\/ivacaftor therapy in adults with cystic fibrosis","volume":"21","author":"Wucherpfennig","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2026012203282184300_bib28","first-page":"834","article-title":"Imaging of cystic fibrosis lung disease and clinical interpretation","volume":"188","author":"Wielp\u00fctz","year":"2016","journal-title":"R\u00f6fo"},{"key":"2026012203282184300_bib29","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1164\/rccm.201807-1203OC","article-title":"Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study","volume":"199","author":"Stahl","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203282184300_bib30","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S2213-2600(19)30187-0","article-title":"Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"7","author":"Ratjen","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2026012203282184300_bib31","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1183\/09031936.03.00049502","article-title":"Evaluation of ventilation maldistribution as an early indicator of lung disease in children with cystic fibrosis","volume":"22","author":"Gustafsson","year":"2003","journal-title":"Eur Respir J"},{"key":"2026012203282184300_bib32","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1136\/thx.2007.077784","article-title":"Multiple-breath inert gas washout and spirometry versus structural lung disease in cystic fibrosis","volume":"63","author":"Gustafsson","year":"2008","journal-title":"Thorax"},{"key":"2026012203282184300_bib33","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1136\/thoraxjnl-2012-202345","article-title":"Multiple-breath washout measurements can be significantly shortened in children","volume":"68","author":"Yammine","year":"2013","journal-title":"Thorax"},{"key":"2026012203282184300_bib34","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S2213-2600(21)00069-2","article-title":"Long-term safety of lumacaftor-ivacaftor in children aged 2-5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study","volume":"9","author":"Hoppe","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2026012203282184300_bib35","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/S0140-6736(09)60327-5","article-title":"Cystic fibrosis","volume":"373","author":"O\u2019Sullivan","year":"2009","journal-title":"Lancet"},{"key":"2026012203282184300_bib36","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"key":"2026012203282184300_bib37","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1164\/rccm.201710-1983OC","article-title":"Effects of lumacaftor-ivacaftor therapy on cystic fibrosis transmembrane conductance regulator function in Phe508del homozygous patients with cystic fibrosis","volume":"197","author":"Graeber","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203282184300_bib38","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.jcf.2017.06.011","article-title":"Pancreatic insufficiency in cystic fibrosis","volume":"16","author":"Singh","year":"2017","journal-title":"J Cyst Fibros"},{"key":"2026012203282184300_bib39","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"2026012203282184300_bib40","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012203282184300_bib41","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 open-label study of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203282184300_bib42","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1164\/rccm.202110-2249OC","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy on CFTR function in patients with cystic fibrosis and one or two F508del alleles","volume":"205","author":"Graeber","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203282184300_bib43","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1164\/rccm.202202-0392OC","article-title":"Efficacy and safety of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis heterozygous for F508del and a minimal function mutation: a phase 3b, randomized, placebo-controlled study","volume":"206","author":"Mall","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203282184300_bib44","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/ppul.25285","article-title":"Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype","volume":"56","author":"McGarry","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"2026012203282184300_bib45","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jcf.2018.05.003","article-title":"Multicentre standardisation of chest MRI as radiation-free outcome measure of lung disease in young children with cystic fibrosis","volume":"17","author":"Wielp\u00fctz","year":"2018","journal-title":"J Cyst Fibros"},{"key":"2026012203282184300_bib46","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1152\/japplphysiol.00338.2021","article-title":"Correction of sensor crosstalk error in Exhalyzer D multiple-breath washout device significantly impacts outcomes in children with cystic fibrosis","volume":"131","author":"Wyler","year":"2021","journal-title":"J Appl Physiol (1985)"},{"key":"2026012203282184300_bib47","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1016\/j.jcf.2021.08.033","article-title":"Impact of cross-sensitivity error correction on representative nitrogen-based multiple breath washout data from clinical trials","volume":"21","author":"Robinson","year":"2022","journal-title":"J Cyst Fibros"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/20\/8\/1144\/66283766\/annalsats_20_8_1144.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/20\/8\/1144\/66283766\/annalsats_20_8_1144.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:29:34Z","timestamp":1769070574000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/20\/8\/1144\/8414759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":47,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8,1]]},"published-print":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.202208-684oc","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8]]},"published":{"date-parts":[[2023,8,1]]},"assertion":[{"value":"2022-08-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}